|
INNOVATION
Incipient to Overt: Angiotensin II receptor blocker, Telmisartan, Investigation On type 2 diabetic Nephropathy
Ongoing trial
 |
Author(s) |
Makino, H, Haneda M, Babazono T, Moriya T, Ito S, Iwamoto Y, Kawamori R, Takeuchi M, Katayama S
|
 |
Title(s) |
The telmisartan renoprotective study from incipient nephropathy to overt nephropathy – rationale, study design, treatment plan and baseline characteristics of the incipient to overt: angiotensin II receptor blocker, telmisartan, investigation on type 2 diabetic nephropathy (INNOVATION) study |
|
Reference(s) |
J Int Med Res 2005;33:677–86
|
|
Disease |
Diabetes mellitus
|
|
Purpose |
To assess whether telmisartan delays the progression of renal disease in hypertensive or normotensive Japanese patients with type 2 diabetes
|
|
Study design |
Randomised, double-blind, placebo-controlled |
|
Follow-up |
Aim 124 weeks |
|
Patients |
Aim 450 patients, aged 30–74 years, with type 2 diabetes, urinary albumin to creatinine ratio of 100–300 mg/g and serum creatinine < 1.5 mg/dl for men and < 1.3 mg/dl for women |
|
Treatment regimen |
Telmisartan, 20 mg/day, titrated to 40 or 80 mg/day, or placebo |
|
Results |
Not yet available |
|
|
|
